RTI Biologics Beats on Revenue, Matches Expectations on EPS
RTI Biologics (NAS: RTIX) reported earnings on April 25. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), RTI Biologics beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share dropped. GAAP earnings per share dropped.
Gross margins expanded, operating margins contracted, net margins contracted.
RTI Biologics logged revenue of $40.4 million. The seven analysts polled by S&P Capital IQ predicted sales of $38.7 million on the same basis. GAAP reported sales were 7.6% lower than the prior-year quarter's $43.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.02. The six earnings estimates compiled by S&P Capital IQ anticipated $0.02 per share. Non-GAAP EPS of $0.02 for Q1 were 50% lower than the prior-year quarter's $0.04 per share. GAAP EPS of $0.03 for Q1 were 25% lower than the prior-year quarter's $0.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.5%, 150 basis points better than the prior-year quarter. Operating margin was 2.6%, 400 basis points worse than the prior-year quarter. Net margin was 3.6%, 100 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $43.1 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $179.0 million. The average EPS estimate is $0.17.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 211 members out of 223 rating the stock outperform, and 12 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.96.
Looking for alternatives to RTI Biologics? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add RTI Biologics to My Watchlist.
The article RTI Biologics Beats on Revenue, Matches Expectations on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.